Parallax Volatility Advisers
ARCT icon

Parallax Volatility Advisers’s Arcturus Therapeutics ARCT Stock Holding History

Parallax Volatility Advisers’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,700
Closed -$124K – 2819
2015
Q2 		$124K Buy
+2,700
New +$124K ﹤0.01% 2174

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Parallax Volatility Advisers's ARCT Position: Q3 2018 in Review

Parallax Volatility Advisers sold out of Arcturus Therapeutics (ARCT) in Q3 2018, closing a stake of 1,900 shares — an estimated $16K sold.

Parallax Volatility Advisers first reported a position in ARCT in Q4 2017 and held it in 3 quarters. The position peaked at $16K in Q2 2018. 22 funds tracked by Wall St. Rank hold ARCT as of Q3 2018.

  • Parallax Volatility Advisers reported no remaining Arcturus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,900 Arcturus Therapeutics shares in Q3 2018, an estimated $16K.
  • Parallax Volatility Advisers first reported a position in Arcturus Therapeutics in Q4 2017 and held it in 3 quarters.
  • Parallax Volatility Advisers's Arcturus Therapeutics position peaked at $16K in Q2 2018.
  • 22 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2018.

Based on Parallax Volatility Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.